tirzepatide vision loss and changes Weight-Loss Drug Linked to Lower Risk of Eye Disease in Patients with Diabetes Our vitreoretinal surgeon explains what

If tablets are priced lower than injections, they may become attractive for patients who are stable on treatment and want a needle-free option

The transition from phentermine to GLP-1 is well-established in clinical practice, and patients who responded well to appetite suppression on phentermine typically respond even better to GLP-1 medications

If you already injected the wrong dose This is more complicated and depends on how far off you were

These successes are even more pronounced in those treated with tirzepatide, with nearly 60% of patients losing 20% of their weight and nearly 40% losing even more than 25% of their initial weight (Figure 6B)